PCSK9 Inhibitors

#134 - James O’Keefe, M.D.: Preventing cardiovascular disease and the risk of too much exercise

Peter Attia MD

A class of drugs that prolong the life of LDL receptors, thus elegantly lowering cholesterol by removing it from circulation without impairing the cell's ability to make cholesterol.

#129 - Tom Dayspring, M.D.: The latest insights into cardiovascular disease and lipidology

Peter Attia MD

A class of drugs that lower LDL cholesterol and ApoB by increasing the number of LDL receptors on liver cells, also effective in lowering Lp(a) levels.

#112 – Ned David, Ph.D.: How cellular senescence influences aging, and what we can do about it

Peter Attia MD

A class of drugs mentioned in the context of the challenges of drug development for atherosclerosis due to moderate uptake and high cost.

Dr. Peter Attia — Longevity Drugs, Alzheimer's Disease, and More

Tim Ferriss

A class of drugs that reduce apoB levels by inhibiting a protein that degrades LDL receptors on the liver, leading to more particles being cleared from circulation, with no observed side effects and mimicking natural genetic mutations.

#24 – Tom Dayspring, M.D., FACP, FNLA – Part V of V: Lp(a), inflammation, oxLDL, remnants, and more

Peter Attia MD

Drugs that increase LDL receptor availability and can potentially lower Lp(a) levels, though not their primary indication.

#23–Tom Dayspring Part IV of V: statins, Zetia, PCSK9 inhibitors, niacin, cholesterol & the brain

Peter Attia MD

A class of drugs that enhance the clearance of apoB-containing particles by preventing the degradation of LDL receptors, leading to significantly lower LDL cholesterol and reduced cardiovascular events, even in patients already on statins.

#83 – Bill Harris, Ph.D.: Omega-3 fatty acids

Peter Attia MD

A class of drugs that have significantly impacted residual risk for cardiovascular disease, mentioned in comparison to EPA's effects on event reduction.

Exercise, Nutrition, Hormones for Vitality & Longevity | Dr. Peter Attia

Andrew Huberman

A class of highly potent injectable drugs that block PCSK9 protein, preventing the degradation of LDL receptors and leading to significant reductions in LDL cholesterol.

#07 – Deep Dive: Lp(a) — what every doctor, and the 10-20% of the population at risk, needs to know

Peter Attia MD

A class of drugs that lower LDL and can reduce Lp(a) by approximately 30-50%, by inhibiting PCSK9 which degrades LDL receptors and potentially other Lp(a) clearance receptors.

Dr. Peter Attia on Mastering Longevity – Insights on Cancer Prevention, Heart Disease, and Aging

FoundMyFitness

A class of drugs developed from Helen Hobbs' discovery that degrade LDL receptors, effectively lowering ApoB and LDL cholesterol with virtually no side effects, but are currently expensive.

334 - Cardiovascular disease, the number one killer: development, biomarkers, apoB, and more

Peter Attia MD

255-Latest therapeutics in CVD, APOE’s role in Alzheimer’s disease, familial hypercholesterolemia

Peter Attia MD

A class of drugs whose safety and efficacy were established in trials led by John Kastelein, used to treat FH and other hypercholesterolemia.

230 ‒ Cardiovascular disease in women: prevention, risk factors, lipids, and more

Peter Attia MD

A class of injectable lipid-lowering drugs (monoclonal antibodies) that significantly lower LDL (50-60%) and Lp(a) (25%), with proven cardiovascular outcome benefits in high-risk patients.

229 ‒ Understanding cardiovascular disease risk, cholesterol, and apoB

Peter Attia MD

A class of injectable medications that significantly lower LDL cholesterol and ApoB levels, often used for patients with high cardiovascular risk or genetic lipid disorders.